The era of high gross profit for high-value consumables has passed

In the past two years, mass procurement has caused a hurricane in the medical industry. The most obvious impact is that the prices of medical supplies have significantly declined, making it a "price butcher". In such a situation, it is highly likely that the medical device sector will repeat itself, and the centralized procurement of coronary stents is only the beginning.

After the centralized procurement, the reduction of expenses that originally belonged to doctors will affect the usage of the entire stent market. It seems that no wonder the news of centralized procurement has caused such a big reaction in the capital market.

Why are there such high sales expenses in the middle? You naturally understand that layered benefits can be said to be a convention in the pharmaceutical industry. The huge expenses are actually unnecessary expenses for patients, and price reductions are inevitable. The centralized procurement of high-value consumables has been brewing for a long time.